Form 4: Avalo Therapeutics CEO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Avalo Therapeutics CEO Garry Arthur Neil was granted stock options and restricted stock units on August 13, 2024, according to a Form 4 filing.
Summary
- Garry Arthur Neil, CEO and Chairman of the Board of Avalo Therapeutics, Inc., received stock options and restricted stock units (RSUs) on August 13, 2024.
- The stock option grants him the right to buy 500,400 shares of common stock at an exercise price of $9.88 per share.
- These options vest 25% on March 28, 2025, and then 1/36 monthly thereafter, contingent upon continued service.
- He also received 194,600 RSUs, each representing a contingent right to receive one share of common stock upon vesting.
- The RSUs vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, also subject to continued service.
- The filing also notes that the amount of beneficial securities owned in Table I has been adjusted to reflect a 1-for-240 reverse stock split on December 28, 2023.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of executive compensation. The grants could be seen as positive for aligning management with shareholder interests, but there's no immediate impact on the company's financials.
Positives
- The grant of stock options and RSUs to the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Future Outlook
The vesting schedules for both the stock options and RSUs are contingent upon the Reporting Person's continued service.
Industry Context
Granting stock options and RSUs is a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
- Comparing Avalo Therapeutics' executive compensation to similar-sized biotech companies like Galera Therapeutics or Veru Inc. could provide a benchmark for assessing the reasonableness of the grants.
- Industry surveys from organizations like Radford or Pearl Meyer provide data on compensation trends and benchmarks for various executive roles in the biotech sector.
Stakeholder Impact
- Shareholders may view the grants as a positive sign of incentivizing management.
- Employees may see the grants as a reflection of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| December 28, 2023 | 1-for-240 reverse stock split |
| August 13, 2024 | Date of transaction: Grant of stock options and RSUs |
| March 28, 2025 | First vesting date for 25% of stock options and 1/3 of RSUs |
| March 28, 2026 | Second vesting date for 1/3 of RSUs |
| March 28, 2027 | Final vesting date for 1/3 of RSUs |
| August 13, 2034 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.